JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

Search

Guardant Health Inc

Затворен

СекторЗдравеопазване

72.17 4.31

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

69.34

Максимум

72.53

Ключови измерители

By Trading Economics

Приходи

-4.7M

-100M

Продажби

29M

232M

Марж на печалбата

-43.044

Служители

1,999

EBITDA

22M

-89M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+5.6% upside

Дивиденти

By Dow Jones

Следващи печалби

29.10.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

3.3B

8.8B

Предишно отваряне

67.86

Предишно затваряне

72.17

Настроения в новините

By Acuity

21%

79%

45 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Guardant Health Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.10.2025 г., 20:49 ч. UTC

Печалби

Correction to Thermo Fisher Article on Oct. 22

23.10.2025 г., 23:51 ч. UTC

Пазарно говорене

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23.10.2025 г., 23:49 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

23.10.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23.10.2025 г., 23:37 ч. UTC

Пазарно говорене

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23.10.2025 г., 22:58 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

23.10.2025 г., 22:57 ч. UTC

Пазарно говорене

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23.10.2025 г., 22:49 ч. UTC

Придобивния, сливания и поглъщания

How Trump Sparked a New Era of State Capitalism -2-

23.10.2025 г., 22:49 ч. UTC

Придобивния, сливания и поглъщания

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23.10.2025 г., 22:17 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23.10.2025 г., 21:41 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23.10.2025 г., 21:05 ч. UTC

Печалби

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23.10.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

23.10.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

23.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

23.10.2025 г., 20:35 ч. UTC

Печалби

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23.10.2025 г., 20:28 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23.10.2025 г., 20:15 ч. UTC

Пазарно говорене
Печалби

Global Commodities Roundup: Market Talk

23.10.2025 г., 20:10 ч. UTC

Печалби

Newmont Mining 3Q Adj EPS $1.71

23.10.2025 г., 20:10 ч. UTC

Печалби

Newmont Mining 3Q Sales $5.52B

23.10.2025 г., 20:10 ч. UTC

Печалби

Newmont Mining 3Q EPS $1.67

23.10.2025 г., 20:09 ч. UTC

Печалби

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23.10.2025 г., 20:07 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

23.10.2025 г., 20:07 ч. UTC

Пазарно говорене
Печалби

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23.10.2025 г., 20:07 ч. UTC

Печалби

Blackstone Looks to IPOs for Investment Exits -- Update

23.10.2025 г., 20:05 ч. UTC

Печалби

Intel 3Q Gross Margin 38.2% >INTC

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel: 4Q Guidance Excludes Altera >INTC

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel Sees 4Q Adj EPS 8c >INTC

Сравнение с други в отрасъла

Ценова промяна

Guardant Health Inc Прогноза

Ценова цел

By TipRanks

5.6% нагоре

12-месечна прогноза

Среден 71.84 USD  5.6%

Висок 90 USD

Нисък 60 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Guardant Health Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

21 ratings

21

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

38.86 / 47.41Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

45 / 371 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Среден

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat